Presented by EPION and CCEIP
Building Success Together
from Knowledge to Innovation
5875 Airport Rd
Mississauga, ON L4V 1N1
May May 15 | 10:00 – 16:30
- Apply new clinical tools developed specifically for early phase psychosis intervention
- Identify solutions to barriers in consideration of the integration of clinical tools into everyday workflow.
- Identify clients who would benefit from a documented formal assessment of:
- Relapse Risk – Ashok Malla
- Appropriate Antipsychotic Therapy – Ofer Agid
- Medication Side Effects – Phil Tibbo
- Client Acceptance – Howard Margolese
Ofer Agid, MD, FRCPC
Staff Psychiatrist, Clinician Scientist
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), University of Toronto
Dr. Agid is staff psychiatrist and a clinician scientist in the Schizophrenia Program at the Centre for Addiction and Mental Health in Toronto. He is also Associate Professor in the Department of Psychiatry, University of Toronto. As the medical leader in the First-Episode Schizophrenia program, Dr. Agid initiated an algorithm-based treatment approach for first-episode schizophrenia while collecting extensive clinical data regarding treatment response. This systematic and standardized approach has resulted in a large and comprehensive database; the published data to date have provided clear, empiric evidence that clinicians can use in approaching the pharmacological management of first-episode schizophrenia.
Dr. Agid’s research focus is psychopharmacology in schizophrenia, specifically early response to antipsychotic medications and early predictors of response. He is also involved in investigating patterns of non-adherence and placebo response, psychopharmacological mechanism of action of antipsychotics using brain imaging techniques and examining value systems and happiness in schizophrenia.
Chiachen Cheng, MD, FRCPC, MPH
Child & Adolescent, Adult Psychiatrist / Physician Researcher
First Place Clinic & Regional Resource Centre / St. Joseph’s Care Group, Thunder Bay
Dr. Chiachen (Chi) Cheng is an Adolescent & Adult Psychiatrist and Physician Researcher. Dr. Cheng completed her Psychiatry residencies at McMaster University, a clinical fellowship in Early Psychosis Intervention (EPI) at McMaster University, and a Masters of Public Health at Harvard University. Dr. Cheng moved to Northwestern Ontario in 2006 to help implement the only EPI program in a rural/northern low-population-density-area that is the size of France.
Dr. Cheng’s research interests are in Early Psychosis Intervention (EPI) and evidence based practice as it interfaces with youth mental health policy. Her research has examined program implementation and development, fidelity to EPI standards, evaluation of EPI training for healthcare workers, delivery of EPI services in rural and remote regions, and pathways to care among vulnerable populations (e.g., youth, Indigenous people). In 2012, Dr. Cheng was awarded a New Investigator Grant from the Sick Kids Foundation and Canadian Institutes of Health Research for “The NorthBEAT Project”, which identified the mental health service needs of youth in Northern Ontario.
Ashok Malla, MD, FRCPC
Prevention and Early Intervention Program for Psychoses (PEPP-Montreal), McGill University
Dr. Malla is a Professor of Psychiatry at McGill University, where he holds a Tier 1 Canada Research Chair in Early Psychosis, with a cross appointment in Department of Epidemiology and Biostatistics. He is also the Director of the Prevention and Early intervention Program for Psychoses (PEPP-Montréal) at the Douglas Mental Health University Institute. Dr. Malla focuses his studies on the early phases of psychotic disorders, such as schizophrenia, and on prevention and early intervention of these severe illnesses. He is an international leader in the development of comprehensive programs for, and research in, early intervention in psychosis.
Dr. Malla’s clinical and research interests have been primarily related to pursuing the goal of understanding and integrating neurobiological and psychosocial aspects of causation and outcome in psychotic disorders, with special emphasis on early phase psychosis. He has published 225 peer-reviewed articles, held many peer reviewed research grants including a current NIH grant for examining differences in outcome in psychotic disorders across cultures between Chennai, India and Montréal.
Howard Margolese, MD, CM, MSc, FRCPC
Early Psychosis and Schizophrenia Spectrum Program (EPSSP), McGill University
Dr. Howard Margolese, an associate Professor in the Department of Psychiatry of McGill University, is the medical director of the McGill University Health Center (MUHC) Early Psychosis and Schizophrenia Spectrum Program (EPSSP) and Director of the PEPP-MUHC first episode psychosis program. He is also director of the Clinical Psychopharmacology and Therapeutic Units’ consultation service. He is currently the program director of the McGill RCPSC Clinical Pharmacology residency program. In his clinical work Dr. Margolese specializes in psychopharmacology consultation of treatment resistance or complex psychopharmacology regimens, first episode psychosis, and chronic and treatment resistant schizophrenia.
Dr. Margolese’s research interests include drug-induced movement disorders, pharmacotherapy of schizophrenia, and adverse effects of psychotropic medications. He has given numerous lectures and presentations both nationally and internationally, published over 50 articles, and letters to the editor, as well as several book chapters. He is a peer reviewer for several leading psychiatric journals.
Philip Tibbo, MD FRCPC
Director / Co-Director
Nova Scotia Early Psychosis Program / Nova Scotia Psychosis Research Unit
Dr. Tibbo is a Professor in the Department of Psychiatry with a cross-appointment in Psychology at Dalhousie University and an Adjunct Professor in Department of Psychiatry at the University of Alberta. He is also Director of the Nova Scotia Early Psychosis Program (NSEPP) and co-director of the Nova Scotia Psychosis Research Unit (NSPRU). In 2008, Dr. Tibbo was named the first Dr. Paul Janssen Chair in Psychotic Disorders at Dalhousie University in Halifax, Nova Scotia. In this position, Dr. Tibbo leads an internationally recognized program of research into the causes and treatments of psychotic disorders. Dr. Tibbo is a 2015 recipient of the Michael Smith Award from the Schizophrenia Society of Canada for research and leadership in schizophrenia.
Dr. Philip Tibbo’s areas of research include application of in vivo brain neuroimaging techniques to study psychosis as well as research interests in co-morbidities in schizophrenia, psychosis genetics, addictions and psychosis, stigma and burden, pathways to care, education, and non-pharmacological treatment options.